The authors analyzed the incidence of sexual dysfunction (SD) with different selective serotonin reuptake inhibitors (SSRIs; fluoxetine, fluvoxamine, paroxetine, and sertraline) and hence the qualitative and quantitative changes in SD throughout time in a prospective and multicenter study. Outpatients (192 women and 152 men; age = 39.6 +/- 11.4 years) under treatment with SSRIs were interviewed with an SD questionnaire designed for this purpose by the authors and that included questions about the following: decreased libido, delayed orgasm or anorgasmia, delayed ejaculation, inability to ejaculate, impotence, and general sexual satisfaction. Patients with the following criteria were included: normal sexual function before SSRI intake, exclusive treatment with SSRIs or treatment associated with benzodiazepines, previous heterosexual or self-erotic current sexual practices. Excluded were patients with previous sexual dysfunction, association of SSRIs with neuroleptics, recent hormone intake, and significant medical illnesses. There was a significant increase in the incidence of SD when physicians asked the patients direct questions (58%) versus when SD was spontaneously reported (14%). There were some significant differences among different SSRIs: paroxetine provoked more delay of orgasm or ejaculation and more impotence than fluvoxamine, fluoxetine and sertraline (chi 2, p < .05). Only 24.5% of the patients had a good tolerance of their sexual dysfunction. Twelve male patients who suffered from premature ejaculation before the treatment preferred to maintain delayed ejaculation, and their sexual satisfaction, and that of their partners, clearly improved. Sexual dysfunction was positively correlated with dose. Patients experienced substantial improvement in sexual function when the dose was diminished or the drug was withdrawn. Men showed more incidence of sexual dysfunction than women, but women's sexual dysfunction was more intense than men's. In only 5.8% of patients, the dysfunction disappeared completely within 6 months, but 81.4% showed no improvement at all by the end of this period. Twelve of 15 patients experienced total improvement when the treatment was changed to moclobemide (450-600 mg/day), and 3 of 5 patients improved when treatment was changed to amineptine (200 mg/day).
Genotype · environment interaction (GEI) affects marketable fruit yield and average fruit weight of both hybrid and open-pollinated (OP) tomato genotypes. Cultivars vary significantly for marketable fruit yield, with hybrid cultivars having, on average, higher yield than OP cultivars. However, information is scanty on environmental factors affecting the differential response of tomato genotypes across environments. Hence, the aim of this research was to use factorial regression (FR) and partial least squares (PLS) regression, which incorporate external environmental and genotypic covariables directly into the model for interpreting GEI. In this research, data from an FAO multi-environment trial comprising 15 tomato genotypes (7 hybrid and 8 OP) evaluated in 18 locations of Latin America and the Caribbean were analyzed using FR and PLS. Environmental factors such as days to harvest, soil pH, mean temperature (MET), potassium available in the soil, and phosphorus fertilizer accounted for a sizeable portion of GEI for marketable fruit yield, whereas trimming, irrigation, soil organic matter, and nitrogen and phosphorus fertilizers were important environmental covariables for explaining GEI of average fruit weight. Locations with relatively high minimum and mean temperatures favored the marketable fruit yield of OP heat-tolerant lines CL 5915-223 and CL 5915-93. An OP cultivar (Catalina) and a hybrid (Apla) showed average marketable fruit yield across environments, while two hybrids (Sunny and Luxor) exhibited outstanding marketable fruit yield in high yielding locations (due to lower temperatures and higher pH) but a sharp yield loss in poor environments. Two stable hybrid genotypes in high yielding environments, Narita and BHN-39, also showed high and stable yield in average and low yielding environments.
Homocystinuria due to cystathionine β-synthase deficiency is an inborn error of metabolism first described almost 50 years ago, which involves the accumulation of plasma homocysteine and other metabolites. Without early detection and appropriate treatment, common and sometimes lethal consequences include ocular abnormalities, osteoporosis, developmental delays, marfanoid phenotype, vascular disease, and mental retardation. Almost 50% of subjects develop a psychiatric disorder during their life, but only 2.8% present a psychiatric symptom as the initial manifestation. Among this group, psychotic disorders are infrequent. We describe the case of a 17-year-old boy presenting with a first episode psychosis and an unknown homocystinuria due to cystathionine β-synthase deficiency, which led to a lethal outcome.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.
hi@scite.ai
10624 S. Eastern Ave., Ste. A-614
Henderson, NV 89052, USA
Copyright © 2024 scite LLC. All rights reserved.
Made with 💙 for researchers
Part of the Research Solutions Family.